Claudio Gobbi

Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis

Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study

Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age‐ and <scp>BMI</scp> ‐Corrected <i>Z</i> Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response

Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis

Visual migraine aura iconography: A multicentre, cross-sectional study of individuals with migraine with aura

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis

Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)

Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis

Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial